The African pygmy hedgehog (
Atelerix albiventris)
is known to have a
high incidence of tumor. However, investigating the tumors of this species has been
constrained by the limited availability of research materials such as cell lines and
genome information. In this study, we successfully established a novel cell line from a
histiocytic sarcoma (HS) of an African pygmy hedgehog, allowing us to conduct a drug
screening. We investigated using FDA-approved drug library screening to determine which
anticancer drug this tumor cell line is sensitive to, and as a result of apoptosis
experiments, bortezomib among the three proteasome inhibitors was found to induce cell
death of cancer cells by significantly increasing caspase-3 cleavage
(
P
<0.01). Thus, we elucidated that the proteasome inhibitors,
particularly bortezomib, exhibit anti-tumor effects on a cell line derived from an HS in
an African pygmy hedgehog through a mechanism comparable to that described in human
tumors. This study reports the first characterized cell line from the African pygmy
hedgehog and also highlights the potential utility of bortezomib as an anti-tumor
treatment for HS in this species.